A clinical-stage biopharmaceutical company has reported significant progress in developing innovative therapies for prostate cancer, focusing on previously intractable targets.

The company has developed a first-in-class ERG-targeted protein degrader for prostate cancer (PROTAC). ERG gene fusions are present in approximately 40-50% of prostate cancer cases and are associated with disease progression. Preclinical models have shown that their ERG degrader effectively reduces ERG protein levels, leading to significant antitumor activity. This program is advancing toward clinical trials, aiming to offer a novel treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC).

They are already testing in a Phase 1/2 clinical trial FOG-001 the first direct inhibitor of the β-catenin/TCF4 complex, a critical driver in various cancers (including prostate cancer), but the trial at the momenti is for colorectal cancer only.

These developments highlight the potential of targeting previously undruggable proteins in prostate cancer, offering hope for more effective treatments in the future.

Source.